Evolution of clinical trials was a major theme among executives who at the end of 2021 shared their predictions for 2022. Remote, or decentralized, trials was a common talking point, as was the harnessing of technological advances in capturing and analyzing data.
Ross Pettit, deputy president of Eisai Co., Ltd. precision oncology subsidiary H3 Biomedicine Inc, summed up some of...